The short version of half-life fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Although these are both aspects of earthworm activities the net effect is important to ascertain, in particular in the frame of organic matter disappearance linked to global warming. It seems that there is now a consensus about the prominent role of earthworms in carbon sequestration due to the fact that part of organic matter is mineralized at or near the soil surface while the major part is incorporated in the deep soil where it is stabilized by links with clay minerals.
This "water mafia" controls major infrastructure projects like dam construction, prioritizing financial and political gains over environmental and social considerations. The IRGC's dominance undermines sustainable water policies, contributing to Iran's ongoing water crisis and highlighting the complex interplay between power, corruption, and resource management.
During the 2025–2026 Iranian protests, Trump repeatedly warned the Iranian authorities that the U.S. would "intervene" if the regime did not halt its crackdown on protesters. On January 16, 2026, Trump announced that the Iranian leadership had reportedly canceled over 800 planned executions. On February 28, 2026, Trump launched a major attack on Iran with Israel with the stated goal of regime change. On March 21, 2026, Trump announced a 48-hour ultimatum on Truth Social calling for Iran to open the Strait of Hormuz, threatening the destruction of Iranian power infrastructure. Over the following week, specifically on March 23 and 26, Trump announced two different extensions to the ultimatum. On March 26, an official pause on "the period of Energy Plant destruction" until April 2, 2026, was announced on social media, an extension he later stated was a result of Iran allowing oil-carrying ships to safely pass through the Strait of Hormuz. On April 4 and 5, 2026, Trump resumed posting threats of US attack on Iranian infrastructure, stating April 7, 2026, as the deadline for the Strait of Hormuz to be opened. On April 7, Trump posted to Truth Social that "a whole civilization will die tonight, never to be brought back again", causing domestic concern that Trump would use nuclear weapons, and resulting in a number of bipartisan calls for the 25th Amendment to be invoked. The White House confirmed in an official statement that there is currently no consideration of usage of nuclear weaponry.
Sources: en.wikipedia.org
=== Historical preparation === Antoine François, comte de Fourcroy and Louis Nicolas Vauquelin discovered in 1799 that the nitrated crystals were identical to Rouelle's substance and invented the term "urea." Berzelius further improved the purification of urea. In 1817 William Prout determining the chemical composition. In the evolved procedure, urea was precipitated as urea nitrate by adding strong nitric acid to urine. To purify the resulting crystals, they were dissolved in boiling water with charcoal and filtered. After cooling, pure crystals of urea nitrate form. To reconstitute the urea from the nitrate, the crystals are dissolved in warm water, and barium carbonate added. The water is then evaporated and anhydrous alcohol added to extract the urea. This solution is drained off and evaporated, leaving pure urea.
Rauvolfia serpentina, the Indian snakeroot, devil pepper, serpentine wood, Sarpagandha (as known locally) or Chandrika, is a species of flower in the milkweed family Apocynaceae. It is native to the Indian subcontinent and East Asia (from India to Indonesia). Rauvolfia is a perennial undershrub widely distributed in India in the sub-Himalayan regions up to 1,000 metres (3,300 ft). Sarpagandha is used in folk medicine in India for centuries to treat a wide variety of maladies, including snake and insect bites, febrile conditions, malaria, abdominal pain, and dysentery. It was also used as a uterine stimulant, febrifuge, and cure for insanity. The plant was mentioned in Hindu manuscripts as long ago as 1000 BCE.
=== Medical exposure === Though rarer; intravenous therapies such as IV bags, injections, and similar, may introduce thousands or millions of micro and nano plastics directly to the bloodstream, including not only solid, but also liquid PDMS plastics lubricants. This may enhance microplastic exposure due to the direct nature of the delivery, which bypasses bodily defences. Saline IVs have been found to introduce 1,600–8,000 microparticles per mL and 4-73 million nanoparticles per mL in IV, with high levels persisting post-filtration. Even blood collection needles appear to introduce plastic to the bloodstream, despite the fact they take fluids rather than injecting them. As such general exposure from disposable plastic medical equipment appears quite high.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.